Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $21.1250.

A number of brokerages recently issued reports on TLX. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Finally, Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Monday, April 13th.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ TLX opened at $10.90 on Friday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $16.98. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The business’s fifty day moving average price is $10.11 and its 200-day moving average price is $8.74.

Insider Transactions at Telix Pharmaceuticals

In related news, CEO Christian Behrenbruch acquired 33,435 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were acquired at an average price of $14.87 per share, with a total value of $497,178.45. Following the acquisition, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. This trade represents a 0.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Institutional Trading of Telix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Portland Investment Counsel Inc. purchased a new stake in Telix Pharmaceuticals during the 3rd quarter worth about $1,225,000. Mariner LLC bought a new position in Telix Pharmaceuticals in the 4th quarter worth about $274,000. JPMorgan Chase & Co. bought a new position in Telix Pharmaceuticals in the 3rd quarter worth about $243,000. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals in the 2nd quarter worth about $213,000. Finally, Vident Advisory LLC bought a new position in Telix Pharmaceuticals in the 4th quarter worth about $204,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.